Edition:
United Kingdom

Celyad SA (CYAD.BR)

CYAD.BR on Brussels Stock Exchange

23.40EUR
21 Sep 2018
Change (% chg)

€0.18 (+0.78%)
Prev Close
€23.22
Open
€23.32
Day's High
€23.94
Day's Low
€23.32
Volume
21,099
Avg. Vol
50,935
52-wk High
€56.48
52-wk Low
€22.30

Chart for

About

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company's product, C-Cure,... (more)

Overall

Beta: 1.65
Market Cap(Mil.): €493.66
Shares Outstanding(Mil.): 9.52
Dividend: --
Yield (%): --

Financials

  CYAD.BR Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -2.24 -- --
ROI: -17.72 1.79 14.61
ROE: -24.26 3.28 16.33

BRIEF-Celyad Says Grade 4 Adverse Events Occurred In Two THINK Trial Patients, Announces Q1 Business Update

* GRADE 4 SERIOUS ADVERSE EVENTS OCCURRED IN TWO PATIENTS OF CYAD-01 THINK TRIAL OUT OF 20 PATIENTS INCLUDED IN INTERIM SAFETY REPORT

16 May 2018

BRIEF-Celyad Successfully Administers CYAD-01 In First Patients In Shrink And Link Trials

* CELYAD SUCCESSFULLY ADMINISTERS CYAD-01 IN FIRST PATIENTS IN SHRINK AND LINK TRIALS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

03 May 2018

BRIEF-Celyad's CYAD-01 Induced Complete Remission In Relapsed/Refractory AML Patient

* HAEMATOLOGICA PUBLISHES CELYAD THINK STUDY CASE REPORT OF CYAD-01 INDUCED COMPLETE REMISSION IN RELAPSED/REFRACTORY AML PATIENT

27 Apr 2018

BRIEF-Celyad To Present Updates On CYAD-01 At American Association For Cancer Research Annual Meeting

* CELYAD TO PRESENT UPDATES ON CYAD-01 AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2018

29 Mar 2018

Earnings vs. Estimates